December 10, 2012
It's the end of 2012, and that means it's time to take a look back at the year in retrospect. We'll be reading through the naughty and nice lists (we've already checked them twice), counting down the 25 best-performing stocks and the 25 worst-performing stocks in the health care sector this year.
In this segment, Motley Fool health care analysts David Williamson and Max Macaluso take a look at No. 23 on the nice list, Dyax (NASDAQ: DYAX ) , and how this company left investors with more than a little something extra in their stockings this year.
Over the next two years, Dyax competitor Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition protection. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.